Innovent publishes preclinical research results of IBI319 (PD-1/CD137 bispecific antibody) in "Nature Communications"

San Francisco, USA and Suzhou, China November 8, 2021/PRNewswire/ - Cinda Biopharmaceutical Group (Hong Kong Stock Exchange stock code: 01801), a company dedicated to R&D, production and sales for the treatment of tumors, metabolic diseases, A biopharmaceutical company with innovative drugs for major diseases such as autoimmunity, recently announced that its preclinical research results of its anti-PD-1/CD137 bispecific antibody (R&D code: IBI319) have been published in a sub-issue of the internationally renowned academic journal "Nature" "Nature Communications"

Preclinical studies have shown that IBI319 has significantly better efficacy than PD-1 monoclonal antibody, and has good safety and no side effects such as hepatotoxicity

In CT26 and MC38 mouse models, IBI319 showed a synergistic effect of enhancing PD-1 pharmacodynamic activity while activating CD137 signal, promoting the tumor infiltration of T cells and NK cells, and was not as effective as the combination of PD-1 and CD137 monoclonal antibodies.

IBI319 is a new-generation bispecific antibody that targets both PD-1 and CD137.

Xu Wei, the co-corresponding author of this article and the vice president of Cinda Biopharmaceuticals, said: “IBI319 can enhance the pharmacodynamic activity of PD-1 while activating the CD137 signal at the same time.

Professor Wu Yilong, the lead investigator of the phase 1 clinical study of IBI319 (CIBI319A101), the life director of Guangdong Provincial People’s Hospital, and the honorary director of Guangdong Lung Cancer Institute, said: “Although PD-(L)1 immune checkpoint inhibitors are currently This kind of tumor has shown surprising curative effects, but it still faces many new challenges, such as immunogenicity and secondary drug resistance.

About CD137 (4-1BB, TNFRS9)

CD137 is a member of the tumor necrosis factor receptor superfamily.

Due to its powerful immune activation function, CD137 agonistic antibody has been explored clinically for more than ten years, but the early development process is not smooth

About IBI319 (PD-1/CD137 bispecific antibody)

IBI319 is an anti-PD-1/CD137 bispecific antibody jointly developed by Cinda Biopharmaceuticals and Eli Lilly Pharmaceuticals, and is developed in China by Cinda Biopharmaceuticals

About the Phase 1 clinical study of IBI319 (CIBI319A101)

This study is a phase 1a/1b clinical study (CIBI319A101) conducted by Cinda Biopharmaceutical Group in China to evaluate IBI319 in the treatment of subjects with advanced malignant tumors

About Cinda Bio

"Starting from the letter, reaching the line", to develop high-quality biological drugs that the common people can afford is the ideal and goal of Cinda Bio

Since its establishment, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operating model

Innovent has established an internationally advanced high-end biopharmaceutical development and industrialization talent team, including many returned experts, and has cooperated with international partners such as Eli Lilly, Adimab, Incyte, MD Anderson Cancer Center, and Hanmi of South Korea.

Forward-looking statement

The information published in this press release may contain certain forward-looking statements

These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts and understandings of the company’s management on future affairs at the time the statement is made

The company, the directors of the company and employee agents shall not undertake (a) any obligation to correct or update any forward-looking statements contained in this website; and (b) if any forward-looking statements cannot be realized or become incorrect.

Source: Cinda Bio